{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:34:12Z","timestamp":1786480452946,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jceh.2026.103614","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:03:33Z","timestamp":1783955013000},"page":"103614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methodological Considerations in the Interpretation of Non-invasive Surrogate Markers in a Post Hoc Analysis of Pemafibrate in Metabolic Dysfunction\u2013associated Steatotic Liver Disease"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9850-9595","authenticated-orcid":false,"given":"Malaha","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2026.103614_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2026.103525","article-title":"Post Hoc analysis of a phase 2 randomized trial of pemafibrate in metabolic dysfunction-associated steatotic liver disease: associations with platelet count, liver stiffness, and spleen volume","volume":"16","author":"Tanigawa","year":"2026","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2026.103614_bib2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1186\/s12888-024-06263-4","article-title":"Missing outcome data in randomised clinical trials of psychological interventions: a review of published trial reports in major psychiatry journals","volume":"24","author":"Juul","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jceh.2026.103614_bib3","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jceh.2026.103614_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2024.107602","article-title":"Addressing missing outcome data in randomised controlled trials: a methodological scoping review","volume":"143","author":"Medcalf","year":"2024","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jceh.2026.103614_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101761","article-title":"Quality criteria for the measurement of liver stiffness","volume":"46","author":"Boursier","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103614_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221140657","article-title":"Update on the role of elastography in liver disease","volume":"15","author":"Ferraioli","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103614_bib7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"suppl 2","key":"10.1016\/j.jceh.2026.103614_bib8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12072-024-10663-9","article-title":"Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective","volume":"18","author":"Keating","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2026.103614_bib9","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/jcm12083011","article-title":"Effect of exercise on liver function and insulin resistance markers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Hejazi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jceh.2026.103614_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40795-024-00961-8","article-title":"Which dietary patterns fend off nonalcoholic fatty liver disease? A systematic review of observational and interventional studies","volume":"10","author":"Bakhshimoghaddam","year":"2024","journal-title":"BMC Nutr"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:23:57Z","timestamp":1786479837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688326001465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0973688326001465"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103614","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methodological Considerations in the Interpretation of Non-invasive Surrogate Markers in a Post Hoc Analysis of Pemafibrate in Metabolic Dysfunction\u2013associated Steatotic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103614"}}